Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Martin BoegemannSara KhaksarGuillaume BeraAlison BirtleCatherine DopchieLouis-Marie DourtheEls EveraertMartin HatzingerDirko HercherWerner HilgersGeoffrey MatusLaura Garcia AlvarezLaurent AntoniMartin LukacGeneviève PissartPaul RobinsonTony ElliottPublished in: BMC cancer (2019)
This European real-world study provides valuable insights into the characteristics, treatment, and outcomes of chemotherapy-naïve patients with mCRPC who received AAP in routine clinical practice. Treatment effectiveness of AAP in the real-world is maintained despite patients having poorer clinical features at initiation than those observed in the COU-AA-302 trial population.
Keyphrases
- clinical practice
- end stage renal disease
- randomized controlled trial
- chronic kidney disease
- small cell lung cancer
- squamous cell carcinoma
- ejection fraction
- clinical trial
- newly diagnosed
- study protocol
- prognostic factors
- metabolic syndrome
- skeletal muscle
- peritoneal dialysis
- adipose tissue
- type diabetes
- weight loss
- phase ii
- open label
- insulin resistance
- chemotherapy induced